May 26
Hey Kyle. Miss you on the Wizards. If you’re investing in defense, space, and biotech, you should check out @tectonicdefense, @payloadspace, and @decodingbio 🤝🫡
1
4
2,233
May 26
And space and biotech too. Sounds like someone might be reading @tectonicdefense, @payloadspace, and @decodingbio 👀
1
3
3,395
May 21
🧬 👀 BIG NEWS: @tectonicdefense and @payloadspace’s parent company, Arkaea Media Group, has acquired @decodingbio, one of the leading media brands in biotechnology!
Like space and defense tech, biotech is one of the most consequential and fast-moving industries in the world. Decoding Bio has built the only and most influential brand dedicated to the critical intersection between AI and biology. This is where the industry's future is being built, and Decoding Bio's position as the leading voice of that technological transformation will only be strengthened as part of the Arkaea family.
To quote Arkaea CEO @itsmoislam (his full announcement in replies), "Arkaea comes from Archaea, ancient microorganisms that thrive in extreme environments, adapting and persisting where others can't. A fitting origin story for a company built around the hardest industries in the world. Maybe biology was always part of the plan."
Arkaea is a rocket ship, and I can't wait to see where this incredible team takes Tectonic, Payload, Decoding Bio, and whatever's next into the future. There is no ceiling. LET'S GO!!!!! 🚀🔥
1
4
202
A fun conversation with @ZahraKhwaja at @decodingbio together with my colleague @inCiChu about our recent work X-cell!
The real question for the field: are we learning biology, or just doing very sophisticated interpolation?
What I think we showed with X-Cell is genuine transfer: trained on resting T cells, it still predicts the correct directional effects of TCR perturbations in activated T cells — a context-dependent setting where naive additive baselines fail.
More importantly, scaling in perturbation biology is not just about bigger models. It is about biological diversity: more contexts, not just more cells.
Single-gene perturbations are only the surface. The real space is combinatorial, effectively infinite. Experiments alone will never cover it. Models have to navigate it.
That will only work if we build shared perturbation datasets for biology the way the field built PDB for structure.
AlphaFold did not happen in isolation. Neither will the virtual cell.
Link: decodingbio.substack.com/p/s…
2
18
3,423
Mar 6
Thanks to @decodingbio for the FlashPPI write-up in BioByte 150 this week! Worth a read if you missed the earlier posts on what it does and how it works.
1
5
260
Feb 9
“Assume your platform has no value. Its only value shows up through the assets you create.” Our CTO Dan Neil on why real value in biotech comes from outcomes, not platforms or hype. Read the full interview with @decodingbio: decodingbio.substack.com/p/s…
1
3
212
Jan 26
9
1,269
🧪 Think “App Store for AI scientists”
Thanks Decoding Bio @decodingbio for featuring ToolUniverse this week
Read how we are making science more open, tool-driven, and collaborative: decodingbio.substack.com/p/b…
1
7
292
18 Sep 2025
AI & bio: speakers from Pfizer, Novartis, the Broad, Vertex & @formationbio will discuss some key areas where biopharma industry has been successful in developing & applying AI & giving career advice @thebiotechclub panel on Fri. Link ⬇️ cc @dr_alphalyrae @TechBi0 @decodingbio
1
4
23
2,830
16 Sep 2025
Many have tried, few have succeeded..... in SynBio.
Fun to work with an incredible squad @decodingbio to write about the past, present and future of SynBio.
Check out the full bio report in the link below 🧬
Thanks to @pablolubroth @ZahraKhwaja for organizing!
3
7
42
4,625
4 Sep 2025
The @decodingbio annual snapshot is out! It was a privilege being an author this year with @anthonycosta and @DBBurkhardt! Check out our chapter on current research and future direction for virtual cells, and notable work by @arcinstitute, @NOETIK_ai and @Basecamp_Res
2
18
85
17,859
30 Jul 2025
It was great chatting with Najat Khan from @RecursionPharma for @BiotechTV at @decodingbio’ AI x Bio summit at @NYSE last week - check out our interview below.
30 Jul 2025
Last week, at the AI x BIO Summit, hosted by @decodingbio and @NYSE, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD spoke with @BiotechTV about how we’re addressing three core drivers of the high failure rate in drug discovery using data and AI.
Namely:
▪️ Ensuring stronger efficacy predictions by leveraging data and AI to uncover deeper, systems-level insights into disease biology.
▪️ Ensuring safety and tolerability by using generative AI and active learning to design safer, more drug-like molecules.
▪️ Ensuring the right patients for clinical trials, leveraging AI to simulate trials before they start in order to pick the patients who are most likely to benefit.
🔹 Najat spoke about the advantages of Recursion’s proprietary, multimodal dataset and evolution from broadly mapping biology, to mining for insights.
“I remember when I did my PhD, it took 5-6 years to have a crystal structure that was relevant. Here, once you’ve created that dataset, you go from mapping to mining. You turn it into a search problem. Think about how much faster you can do discovery if you have the holistic map in front of you and you have AI agents searching.”
🔹 She also discussed how the latest AI tools allow us to rapidly refine the process of creating highly optimized molecules.
“I’m an organic chemist so I’m always thinking about the number and time and cost to get to the elite candidate. Today we’re synthesizing only 200 or 300 [molecules] per program, compared to the thousands it usually takes. That’s completely changing the game in terms of time and cost. Because you are simulating all this – using modules like Boltz-2 and other algorithms, you’re doing all of the triaging in silico and then you only make what you have true conviction in that doesn’t just have tight binding affinity, but is drug-like.”
👉 Check out the full conversation here: biotechtv.com/post/recursion…
3
203
30 Jul 2025
Last week, at the AI x BIO Summit, hosted by @decodingbio and @NYSE, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD spoke with @BiotechTV about how we’re addressing three core drivers of the high failure rate in drug discovery using data and AI.
Namely:
▪️ Ensuring stronger efficacy predictions by leveraging data and AI to uncover deeper, systems-level insights into disease biology.
▪️ Ensuring safety and tolerability by using generative AI and active learning to design safer, more drug-like molecules.
▪️ Ensuring the right patients for clinical trials, leveraging AI to simulate trials before they start in order to pick the patients who are most likely to benefit.
🔹 Najat spoke about the advantages of Recursion’s proprietary, multimodal dataset and evolution from broadly mapping biology, to mining for insights.
“I remember when I did my PhD, it took 5-6 years to have a crystal structure that was relevant. Here, once you’ve created that dataset, you go from mapping to mining. You turn it into a search problem. Think about how much faster you can do discovery if you have the holistic map in front of you and you have AI agents searching.”
🔹 She also discussed how the latest AI tools allow us to rapidly refine the process of creating highly optimized molecules.
“I’m an organic chemist so I’m always thinking about the number and time and cost to get to the elite candidate. Today we’re synthesizing only 200 or 300 [molecules] per program, compared to the thousands it usually takes. That’s completely changing the game in terms of time and cost. Because you are simulating all this – using modules like Boltz-2 and other algorithms, you’re doing all of the triaging in silico and then you only make what you have true conviction in that doesn’t just have tight binding affinity, but is drug-like.”
👉 Check out the full conversation here: biotechtv.com/post/recursion…
1
1
16
3,972
29 Jul 2025
Thank you @decodingbio for covering our launch and reviewing our platform on binder design tasks!
The authors concluded: 'Latent Lab’s new platform speaks for itself.'
Read the full review article here: tinyurl.com/latent-X-decodin…
2
9
965
29 Jul 2025
We're hosting a biotech operator & early scientists mixer with @Pranay_Shahh (@ARIA_research) and @pablolubroth (@decodingbio) at the @IDEALondon @WilbeLAB space! 🧪 🔬
Come drop by tomorrow!
RSVP: lu.ma/3b2ygzcs
3
59
29 Jul 2025
We're hosting a biotech operator & early scientists mixer with @Pranay_Shahh (@ARIA_research) and @pablolubroth (@decodingbio) at the @IDEALondon space!
Come drop by tomorrow!
RSVP: lu.ma/3b2ygzcs
1
5
11
974
23 Jul 2025
Another incredible AI x BIO Summit in the books 🎉
Forever grateful to @ameekapadia, @pablolubroth and the rest of the @decodingbio team for putting on such an amazing event letting @bunsenstudio be apart of it. Always exciting to see our work on the NYSE trading floor.
2
373
23 Jul 2025
@samsinai spoke with @RS_Flinn of @BiotechTV at the @decodingbio AI x Bio Summit hosted at @NYSE about how our AI-powered LEAP platform is transforming gene therapy delivery and enabling a future in which patients have greater agency over their genetic health.
Watch here: biotechtv.com/post/dyno-ther…
22 Jul 2025
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: The Co-Founder and Head of Machine Learning at @Dyno_Tx describes how his company is using AI to design better capsids.
Full video: biotechtv.com/post/dyno-ther…
2
8
640